|
|
Article: Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes.
- Article from:
- Core Evidence
- Article date:
- January 1, 2005
- Author:
CopyrightCOPYRIGHT 2005 Core Medical Publishing. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Abstract
Introduction: Restless legs syndrome (RLS) affects 5-15% of adults, but is often unrecognized and consequently misdiagnosed. The International Restless Legs Scale (IRLS) has been developed and validated to assess the severity of RLS. Currently, the most common treatment for RLS is levodopa, but this may lead to augmentation of symptoms. Pramipexole has been developed as an alternative treatment for patients diagnosed with RLS.
Aims: The objective of this article is to review the evidence of the effectiveness of pramipexole for the clinical management of patients with RLS.
Evidence review: There is clear evidence that pramipexole ...